Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sema-RTx: Oral Semaglutide in Hyperglycaemic Patients After Renal Transplantation
NCT05702931Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of semaglutide in hyperglycemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Mean sensor glucose evaluated by CGM at 14 weeks. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
hyperglycemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05702931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702931.